IDEXX Laboratories, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
February 05, 2024 at 06:30 am EST
Share
IDEXX Laboratories, Inc. reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was USD 901.6 million compared to USD 828.57 million a year ago. Net income was USD 194.52 million compared to USD 172.21 million a year ago. Basic earnings per share from continuing operations was USD 2.34 compared to USD 2.08 a year ago. Diluted earnings per share from continuing operations was USD 2.32 compared to USD 2.05 a year ago.
For the full year, sales was USD 3,660.95 million compared to USD 3,367.32 million a year ago. Net income was USD 845.04 million compared to USD 679.09 million a year ago. Basic earnings per share from continuing operations was USD 10.17 compared to USD 8.12 a year ago. Diluted earnings per share from continuing operations was USD 10.06 compared to USD 8.03 a year ago.
IDEXX Laboratories, Inc. is a world leader in the design, development and marketing of diagnostic test instruments for animal health monitoring and analysis of dairy products and water. Net sales break down by area of application as follows:
- veterinary diagnoses for pets (91.6%);
- water quality analysis (4.6%);
- veterinary diagnoses for livestock and poultry (3.3%): solutions that help detect infectious diseases in ruminants, pigs, poultry and horses. The group also offers test solutions for dairy products;
- other (0.5%).
Net sales by source of income break down between product sales (57.1%) and services (42.9%).
Net sales are distributed geographically as follows: the United States (65.3%), Canada (4.1%), Americas (2.3%), Germany (4.1%), the United Kingdom (3.3%), France (2.7%), Italy (1.5%), Spain (1.4%), Switzerland (0.9%), the Netherlands (0.8%), Europe/Middle East/Africa (4.8%), Australia (2.6%), Japan (2.1%), China (1.2%) and Asia/Pacific (2.9%).
IDEXX LABORATORIES, INC. 
